Extraction and evaluation of mesenchymal stem cells from bone marrow aspirate.

Extraction and evaluation of mesenchymal stem cells from bone marrow aspirate. - MSCs from bone marrow

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000048061

Enrollment

Registered

2022-06-14

Start date

2022-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Musculoskeletal diseases

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. patients undergoing scoliosis surgery in the Department of Orthopaedic Surgery at Keio University Hospital from the time of approval by the Ethics Review Committee until the end of the collaborative study 2. patients between the ages of 16 and 75 years (patients with adolescent idiopathic scoliosis, the most common form of scoliosis, who are 16 years of age or older and who are considered capable of giving informed consent) Patients who have given a full explanation of the sample donation, and who have given written consent to participate in this study of their own free will, based on a thorough understanding of the study (this was established from an ethical standpoint as a basic requirement for conducting the study).

Exclusion criteria

Exclusion criteria: 1. patients who are judged by the physician in charge to be inappropriate to participate in this study (established as a basic requirement for conducting this study) 2. patients with infectious diseases such as hepatitis B, hepatitis C, HIV, HTLV-1, and syphilis (established as a safety precaution for specimen analysts in this study)

Design outcomes

Primary

Measure	Time frame
1) Perioperatively derived cells obtained from scoliosis patients using cell surface antibodies such as CD73, CD90, CD105, and CD271 will be quantified for cellular components using flow cytometry. 2) The content ratio of the obtained mesenchymal stem cell markers and cell characteristics will be analyzed to see if they differ in each tissue to be harvested (e.g., thoracic spine, lumbar spine, iliac bone, etc.). In addition, cell surface antigens will be used as indicators for isolation, and cell functions will be evaluated by culture and transplantation experiments.	—

Measure

Time frame

1) Perioperatively derived cells obtained from scoliosis patients using cell surface antibodies such as CD73, CD90, CD105, and CD271 will be quantified for cellular components using flow cytometry. 2) The content ratio of the obtained mesenchymal stem cell markers and cell characteristics will be analyzed to see if they differ in each tissue to be harvested (e.g., thoracic spine, lumbar spine, iliac bone, etc.). In addition, cell surface antigens will be used as indicators for isolation, and cell functions will be evaluated by culture and transplantation experiments.

—

Secondary

Measure	Time frame
Evaluate gene expression (cell growth factor, bone-related genes, vascular endothelial cell growth factor, anti-inflammatory factor, etc.) and secreted factor components of mesenchymal stem cells isolated with various markers.	—

Countries

Japan

Contacts

Public ContactTsuji Osahiko

Keio University School of Medicine Department of Orthopaedic Surgery

osahiko.z8@keio.jp03-5363-3812

Outcome results